Literature DB >> 12421873

Energy imbalance and prostate cancer.

Elizabeth A Platz1.   

Abstract

In this review, the emerging evidence that excessive energy intake relative to energy expenditure increases the risk of prostate cancer is discussed. The adverse effects of energy imbalance can be inferred from an experimental study demonstrating reduced prostate tumor growth, lower circulating concentrations of insulin-like growth factor-I and decreased expression of vascular endothelial growth factor with energy restriction in transplantable tumor models. The effects of energy restriction on factors mediating greater proliferation relative to apoptosis and angiogenesis suggest that energy imbalance may act late in the carcinogenic pathway. Energy intake also has been evaluated in relation to prostate cancer risk in 23 analytic epidemiologic studies. Among studies reporting effect estimates, 8 of 14 case-control studies support a direct association [top versus bottom quantile, OR(summary) = 1.3; 95% confidence interval (CI), 1.1-1.4], but none of four cohort studies do (RR(summary) = 1.0; 95% CI, 0.8-1.2). The four case-control studies that evaluated advanced disease suggest a higher risk with higher energy intake (OR(summary) = 1.6; 95% CI, 1.2-2.0). However, none of these studies considered the balance of energy intake with body size and physical activity, the major determinants of variability in energy demand. Numerous research questions remain to be addressed, including, Which biological pathways are adversely affected by energy imbalance? Does energy imbalance act early or late in prostate carcinogenesis? What is the optimal energy balance for minimizing risk of clinically important prostate cancer? Evidence is beginning to show that energy intake in excess of expenditure may affect prostate carcinogenesis and, in particular, risk of advanced disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421873     DOI: 10.1093/jn/132.11.3471S

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  7 in total

1.  Obesity-related promotion of aberrant crypt foci in DMH-treated obese Zucker rats correlates with dyslipidemia rather than hyperinsulinemia.

Authors:  Tatiana C L Koch; Karlis Briviba; Bernhard Watzl; Achim Bub; Stephan W Barth
Journal:  Eur J Nutr       Date:  2008-05-15       Impact factor: 5.614

2.  Age-specific physical activity and prostate cancer risk among white men and black men.

Authors:  Steven C Moore; Tricia M Peters; Jiyoung Ahn; Yikyung Park; Arthur Schatzkin; Demetrius Albanes; Albert Hollenbeck; Michael F Leitzmann
Journal:  Cancer       Date:  2009-11-01       Impact factor: 6.860

3.  Dietary Patterns Are Associated with Risk of Prostate Cancer in a Population-Based Case-Control Study in Montreal, Canada.

Authors:  Karine Trudeau; Marie-Claude Rousseau; Christine Barul; Ilona Csizmadi; Marie-Élise Parent
Journal:  Nutrients       Date:  2020-06-27       Impact factor: 5.717

4.  Extent of Food Processing and Risk of Prostate Cancer: The PROtEuS Study in Montreal, Canada.

Authors:  Karine Trudeau; Marie-Claude Rousseau; Marie-Élise Parent
Journal:  Nutrients       Date:  2020-02-28       Impact factor: 5.717

Review 5.  Dietary Factors and Prostate Cancer Development, Progression, and Reduction.

Authors:  Michał Oczkowski; Katarzyna Dziendzikowska; Anna Pasternak-Winiarska; Dariusz Włodarek; Joanna Gromadzka-Ostrowska
Journal:  Nutrients       Date:  2021-02-03       Impact factor: 5.717

6.  Prostate cancer risk related to foods, food groups, macronutrients and micronutrients derived from the UK Dietary Cohort Consortium food diaries.

Authors:  J A Lane; S E Oliver; P N Appleby; M A H Lentjes; P Emmett; D Kuh; A Stephen; E J Brunner; M J Shipley; F C Hamdy; D E Neal; J L Donovan; K-T Khaw; T J Key
Journal:  Eur J Clin Nutr       Date:  2016-09-28       Impact factor: 4.016

Review 7.  Health inequity drives disease biology to create disparities in prostate cancer outcomes.

Authors:  William G Nelson; Otis W Brawley; William B Isaacs; Elizabeth A Platz; Srinivasan Yegnasubramanian; Karen S Sfanos; Tamara L Lotan; Angelo M De Marzo
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.